127 related articles for article (PubMed ID: 33823990)
1. Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.
Perri T; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Fertil Steril; 2021 Aug; 116(2):538-545. PubMed ID: 33823990
[TBL] [Abstract][Full Text] [Related]
2. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
Cibula D; Zikan M; Dusek L; Majek O
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
[TBL] [Abstract][Full Text] [Related]
5. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
Shapira M; Raanani H; Feldman B; Srebnik N; Dereck-Haim S; Manela D; Brenghausen M; Geva-Lerner L; Friedman E; Levi-Lahad E; Goldberg D; Perri T; Eldar-Geva T; Meirow D
Fertil Steril; 2015 Nov; 104(5):1162-7. PubMed ID: 26335130
[TBL] [Abstract][Full Text] [Related]
6. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
[TBL] [Abstract][Full Text] [Related]
7. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
9. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Laitman Y; Michaelson-Cohen R; Levi E; Chen-Shtoyerman R; Reish O; Josefsberg Ben-Yehoshua S; Bernstein-Molho R; Keinan-Boker L; Rosengarten O; Silverman BG; Perri T; Korach J; Mor P; Ephrat Ben-Baruch N; Levy Lahad E; Friedman E;
Cancer; 2019 Mar; 125(5):698-703. PubMed ID: 30489631
[TBL] [Abstract][Full Text] [Related]
10. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Schrijver LH; Antoniou AC; Olsson H; Mooij TM; Roos-Blom MJ; Azarang L; Adlard J; Ahmed M; Barrowdale D; Davidson R; Donaldson A; Eeles R; Evans DG; Frost D; Henderson A; Izatt L; Ong KR; Bonadona V; Coupier I; Faivre L; Fricker JP; Gesta P; van Engelen K; Jager A; Menko FH; Mourits MJE; Singer CF; Tan YY; Foretova L; Navratilova M; Schmutzler RK; Ellberg C; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Rantala J; Osorio A; Hopper JL; Phillips KA; Milne RL; Beth Terry M; Noguès C; Engel C; Kast K; Goldgar DE; van Leeuwen FE; Easton DF; Andrieu N; Rookus MA;
Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488
[TBL] [Abstract][Full Text] [Related]
12. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
13. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gronwald J; Glass K; Rosen B; Karlan B; Tung N; Neuhausen SL; Moller P; Ainsworth P; Sun P; Narod SA; Lubinski J; Kotsopoulos J;
Fertil Steril; 2016 Mar; 105(3):781-785. PubMed ID: 26698676
[TBL] [Abstract][Full Text] [Related]
14. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
15. The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation.
Toss A; Grandi G; Cagnacci A; Marcheselli L; Pavesi S; De Matteis E; Razzaboni E; Tomasello C; Cascinu S; Cortesi L
Oncotarget; 2017 Feb; 8(6):9144-9154. PubMed ID: 27880720
[TBL] [Abstract][Full Text] [Related]
16. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
Park J; Huang D; Chang YJ; Lim MC; Myung SK
Carcinogenesis; 2022 Apr; 43(3):231-242. PubMed ID: 34958358
[TBL] [Abstract][Full Text] [Related]
17. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
18. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
19. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
20. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
